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Introduction
Erythropoiesis counterbalances the continuous loss of aged red blood cells in order to adjust the red cell mass. The production of red blood cells in the bone marrow is under the tight control of the erythropoietin hormone (Epo). This 30.4 kDa highly glycosylated protein 1,2 is synthesized in response to hypoxia by the peritubular interstitial cells of the adult kidney and by fetal liver cells. 3 Treatment with recombinant human Epo (rhuman Epo) is a proven therapy for anemia related to decreased red blood cell production in patients suffering from renal insufficiency. 4, 5 Subcutaneous hormone administration two or three times a week efficiently raises hematocrit and hemoglobin levels, avoiding the need for blood transfusion. Parenteral Epo administration is also indicated for anemia resulting from chronic inflammatory diseases such as cancer or AIDS. 6 Recently, the direct in vivo transfer of the gene encoding Epo via injection of plasmid DNA, 7 or through infection by adenoviral 8, 9 and adeno-associated vec- tors, 10, 11 has provided an alternative to the systemic administration of the recombinant hormone. Similarly ex vivo gene therapy approaches based on the transplantation of myoblasts, [12] [13] [14] smooth muscle cells 15 and fibroblasts 16, 17 genetically engineered to release Epo have led to sustained increases in the hematocrit in normal and anemic animal models.
Polymer encapsulation of subcutaneously implanted cells may improve the safety and reliability of such ex vivo systems. The use of an immunoprotecting synthetic membrane of appropriate molecular weight cut-off shields the transplanted cells from the host immune system without affecting diffusion of small molecules such as nutrients and therapeutic molecules inward and outward of the capsule. This technique allows the use of cell lines from both allogeneic and xenogeneic origin which can be easily grown, genetically engineered and tested for the eventual presence of pathogenic agents. 18, 19 Furthermore, the safety of this approach is based on the cellular rejection of the grafted cells by the host immune system in the unlikely event of capsule breakage. Additionally, suicide genes such as herpes simplex virus thymidine kinase gene (HSV-tk) contained in the transfected plasmid allow cell elimination upon the oral administration of a small molecule, such as ganciclovir, if needed. 20 Provided adequate geometry, the implant can also be retrieved, allowing the interruption of the treatment in case of limit-ing side-effects. This gene therapy approach has already been applied in amyotrophic lateral sclerosis patients through the intrathecal transplantation of polymer encapsulated cells genetically engineered to release neurotrophic factors. 20, 21 In order to test this concept for the peripheral delivery of a bioactive protein, mouse myoblast cell lines (C 2 C 12 ) able to direct high expression of Epo were generated. For that purpose, the mouse and human Epo cDNAs were transfected in vivo into mouse C 2 C 12 myoblasts. Three ubiquitous promoters were tested for their capacity to induce high Epo secretion levels. As previously shown, myoblasts can be differentiated into myotubes upon exposure to low serum containing medium 22 and are able to maintain high transgene expression levels over a long time period, even in vivo. 12, 14, [23] [24] [25] [26] However, cell therapy based on intramuscular injections of genetically modified myoblasts suffers from a major drawback due to their poor engraftment. Myoblast viability rapidly decreases 2 to 3 days after injection and long-term survival depends on the rare fusion events with host muscle cells. [27] [28] [29] The aim of the present work was to investigate the ability of myoblast encapsulation to overcome the shortcomings of free myoblast transplantation.
Results
Construction of myoblasts secreting human or mouse Epo Mouse C 2 C 12 cells were transfected with the pCI-human Epo-ND,pMI-human Epo-ND and pPI-human Epo-ND vectors ( Figure 1 ). The cytomegalovirus (CMV), mouse metallothionein 1 (MT-1) and mouse phosphoglycerate kinase 1 (PGK-1) promoters were chosen for their ability to direct stable and constitutive expression of foreign genes. After selection for neomycin resistance and metho- 6 cells per day) confirming the stability of myoblast transgene expression. Human Epo bioactivity was confirmed by the incubation of culture supernatants with the Epo-dependent murine cell line DaE7 (data not shown). 30 In parallel, the mouse Epo cDNA was introduced into the pPI-ND backbone. The average secretion of C 2 C 12 cells transfected with the pPI-mouse Epo-ND vector was 51 IU per 10 6 cells per day as determined with the human Epo ELISA test cross-reacting with mouse Epo. This result was corrected according to the bioactivity tests performed on the murine DaE7 cell line. The correlation function was 7.637x−0.005 (where x is the ELISA measured value) resulting in an absolute mouse Epo secretion of 390 IU per 10 6 cells per day.
In vivo evaluation of encapsulated C 2 C 12 cells engineered to release mouse Epo
To test their in vivo long-term survival, encapsulated C 2 C 12 cells secreting mouse Epo (390 IU per 10 6 cells per day) were implanted into the dorsal flank of C3H, C57BL/6 and DBA/2J mice. One centimeter long polyether-sulfone capsules were loaded with myoblasts and differentiated in vitro for 3 days. The mean pre-implantation secretion of devices was 52.7 ± 13.9 IU mouse Epo per day (Table 1) . In each group, two control mice received capsules containing nontransfected C 2 C 12 cells. In the three mice strains, mouse Epo delivery induced a rapid and significant increase of the hematocrit, reaching a plateau after 50 to 60 days. Syngeneic (C3H: 91.3 ± 2.0% on day 83; P Ͻ 0.0001) ( Figure 2 ) as well as allogeneic mice (DBA/2J: 92.8 ± 2.1% on day 77, P Ͻ 0.0001; C57BL/6: 87.0 ± 5.7% on day 77, P Ͻ 0.01) (Figures 3 and 4) showed sustained hematocrit levels above 85%. The spontaneous death over time of several DBA/2J and C57BL/6 mice was believed to be associated with abnormally high levels of hematocrit ( Figures 3 and 4) . No significant difference in hematocrit was observed between the syngeneic recipients as compared with allogeneic ones (P Ͼ 0.1 on day 77). After 80 days in vivo, capsules were explanted for further analysis. Independently of the host strain, the mean in vitro mouse Epo secretion was only slightly decreased compared with pre-implantation values, demonstrating stable transgene expression and long-term cell viability even in allogeneic recipients (Table 1) . Released Epo paralleled well with the morphology of the explanted devices, whose histologic examination revealed mainly living myoblasts, with the occasional presence of multinucleated myotubes ( Figure 5 ). Moreover the capsule was surrounded by a neovascular network which had invaded the adjacent subcutaneous tissue ( Figure 5 ). Presence of mouse Epo in the serum was also explored at the time of explantation, 
Figure 4 Long-term monitoring of the hematocrit in C57BL/6 mice implanted with Epo-secreting capsules. Mice received either mouse Epo (n = 6) or human Epo releasing capsules (n = 9)
. Their hematocrits were compared with animals implanted with nontransfected C 2 C 12 myoblasts (n = 2). One mouse was explanted at day 35. and was detectable in half of the implanted mice (ranging from 18 mIU/ml to 254 mIU/ml), but in none of the mice which had received a capsule containing untransfected myoblasts.
In vivo evaluation of encapsulated C 2 C 12 cells secreting human Epo A similar long-term study was performed in the same three stains with the pool of C 2 C 12 cells releasing human Epo (150 IU per 10 6 cells per day). The mean secretion of the capsules was 10.1 ± 6.8 IU human Epo per day. During the 70 days study performed in the syngeneic C3H (H-2 k ) and in the allogeneic C57BL/6 (H-2 b ) mice, none of the mice implanted with human Epo-secreting devices showed significant increase of their hematocrit ( Figures 2  and 4) ; on the contrary, after 20 days, the hematocrit of several animals decreased to abnormally low levels revealing an anemia. This was particularly evident with the C57BL/6 strain reaching 29.2 ± 10.0% on day 63 (P Ͻ 0.05). The sera of these mice demonstrated the presence of IgG antibodies related to the appearance and the severity of anemia (Figure 6 ), suggesting a putative crossreaction of these antibodies with endogeneous mouse Epo.
In DBA/2J mice, the hematocrit increased to 64.3 ± 6.4% (P Ͻ 0.0001) 14 days after implantation, reaching a peak at 70% between days 25 and 40 ( Figure 3 ). A progressive decline was then observed, presumably coinciding with a weaker, compared with the other strains, but still significant immune response against the human protein.
Histological analysis was quite similar to mouse Eposecreting capsules as decribed above and confirmed the presence of viable myoblasts in most explanted devices (data not shown).
Intramuscular injection of mouse EPO secreting cells
In order to test their survival, doses ranging from 0.1 to 8.0 million C 2 C 12 myoblasts secreting mouse Epo were injected intramuscularly into 10 female C3H mice. This strain is syngeneic to C 2 C 12 cells and therefore constitutes an immunocompetent recipient. During the first week after transplantation, hematocrit of injected mice increased to 65% in a way similar to recipients implanted with 0.3 million encapsulated cells. A progressive decrease to basal levels was however observed from day 14 onwards, indicating a poor survival of transferred myoblasts (Figure 7 ). To exclude any immune response directed against minor male antigens (H-Y) potentially expressed by C 2 C 12 myoblasts implanted into female hosts, a similar experiment was performed with male recipients. Doses ranging from 1 to 2 million mouse Eporeleasing myoblasts were injected into four male C3H mice. Similar results to those observed with the female C3H were obtained (data not shown).
Discussion
The present study demonstrates the suitability of encapsulated cell transplantation for the long-term delivery of bioactive Epo in both syngeneic and allogeneic mouse models. The ability of C 2 C 12 myoblasts to express large amounts of Epo has been examined following transfection with different constructs derived from the pCI-Neo vector. The addition of the mutated DHFR gene allowed a stable methotrexate-dependent amplification of the transgene expression, leading to increased Epo secretion. Three different promoters have been tested in the same vector transfected into a pool of C 2 C 12 myoblasts. Following amplification with methotrexate, the constitutive Epo secretion induced by the mouse PGK-1 promoter was 2 and 15 times higher than those driven by MT-1 and CMV promoters, respectively. Moreover transgene expression appears to be remarkably stable after differentiation in low serum-containing medium and over 80 days in vivo.
In order to explore the long-term functionality of hormone-secreting devices, encapsulated myoblasts releasing mouse Epo were implanted in mice of three different syngeneic and allogeneic strains. In all implanted mice, hematocrit levels rose rapidly above 85%. As a consequence of this severe erythrocytosis, some C57BL/6 and DBA/2J mice died from day 28 on.
No significant difference in cell viability was observed over the experiment time course between syngeneic and allogeneic recipients, as judged by the hematocrit values at the time of death, Epo released by the explanted capsules and histologic examination. Whereas a microporous membrane offers an absolute protection against immune response mediated by cell-cell contact and allows the passive diffusion of large nutritive molecules, the exclusion of antibodies and complement is only partial. With the use of myoblasts, the relative lack of major histocompatibility complex expression on the surface of these cells 31 may decrease the stimulation of a humoral immune response in the allogeneic host and then obviate the need for total exclusion of antibodies and complement. Nevertheless, clinical applications of murine myoblasts raise the problem of implanted cell lysis due to the presence of naturally pre-existing antibodies or the induction of antibodies directed against xenogeneic antigens shed from the encapsulated cells. Use of tighter membranes associated with the expression of complement regulatory proteins, such as Complement Receptor 1 (CD35), on the surface of the encapsulated cells may prevent complement-mediated cell lysis. 32, 33 In another set of experiments, myoblasts secreting human Epo were encapsulated and implanted into mice of three different strains. In spite of good cell viability, demonstrated by the histology of explanted devices, the human Epo released by the implant induced only a transient increase of DBA/2J mice hematocrit. No response was observed in C3H mice. The delivery of foreign Epo in C57BL/6 mice led to an anemia after 30 days. These results are in accordance with the immunogenicity of Epo across species observed using in vivo approaches based on adenoviral vectors and syngeneic myoblast transfer. 34, 35 The emergence of anemia could be explained by the cross-reactivity of antibodies directed against the transgene encoded protein with the endogeneous hormone. Interestingly, the immune response severity appears to be strongly dependent on the host mouse strain.
Analysis of explanted devices revealed on overall excellent viability of transplanted cells after 3 months in vivo. The presence in some devices of multinucleated myotubes formation clearly indicates the differentiation of C 2 C 12 myoblasts in a post-mitotic state, avoiding the potential problems of debris accumulation observed with continuously dividing cells. In most cases, the amounts of hormone released at the explantation time point are comparable to the pre-implantation data, confirming the long-term stability of in vivo transgene expression driven by the PGK-1 promoter in C 2 C 12 cells.
Tissue surrounding the implant was characterized by a thin fibrotic layer denoting an adequate capsule engraftment due to favorable polymer biocompatibility. The important vascularization observed around the Eposecreting capsules may be the consequence of the Epo angiogenic activity. [36] [37] [38] Synergistic effects of angiogenic factors normally secreted by C 2 C 12 cells, such as vascular endothelial growth factor (VEGF), should not be discounted. 39 Recent studies were performed in order to demonstrate the feasibility of ex vivo gene therapy approaches based on the intramuscular injection of autologous or syngeneic genetically modified myoblasts. 12, 14, [23] [24] [25] However, although long-term transgene expression could be demonstrated, the number of surviving cells rapidly declines within 2 days after myoblast transplantation. 27, 28, 40 Beside immune response against minor histocompatibility antigens, this technique suffers from the poor engraftment of myoblasts resulting only in rare fusion events with host myogenic cells. Similarly, the only transient increase observed in C3H mice injected with mouse Epo-secreting C 2 C 12 cells probably reflects the short survival of injection myoblasts due to conditions not conducive to myotube formation. On the contrary, encapsulation allows the differentiation of myoblasts in a three-dimensional configuration before implantation, leading to an improved engraftment and long-term Epo release.
This study shows the relevance of species-specific Epo delivery via immunoprotected myoblast implantation for a long-term biological response in a mouse model. In future prospects, human clinical application would benefit from the regulated release of Epo as a function of oxygen tension. The use of hypoxia-inducible promoters may achieve this goal. In preliminary work, the constitutive mouse PGK-1 promoter has been demonstrated to increase gene transcription in an oxygen poor environ-ment and to maintain these characteristics in an in vivo cell therapy model. 41 Treatment of ␤-thalassemic patients may also benefit from the administration of Epo 42 stimulating the ␥-globin chain synthesis, thus giving rise to the production of fetal hemoglobin (HbF; ␣2-␥2). The latter reduces the globin chain imbalance and ineffective erythropoiesis characteristic of homozygous ␤-thalassemia. In a mouse model displaying clinical and biological features similar to those of human ␤-thalassemia intermedia, adminsitration of human Epo raised the hematocrit and led to a normalization of red blood cell shape, being associated with an increase of ␤-minor (fetal-like) globin to ␣-globin ratio and a decrease in membrane-bound ␣-globin. 43 However, repeated injections of large human Epo doses (300-1000 IU/kg) leading to a therapeutic effect are still inaccessible to a wide population of ␤-thalassemic patients because of their considerable cost. 44, 45 Continuous administration of human Epo via encapsulated cells may provide an alternative to such a treatment.
The long-term viability and transgene expression of encapsulated myoblasts following subcutaneous implantation suggests that this technique may also constitute a promising strategy for the long-term systemic delivery of other biologically active molecules such as factor VIII for the treatment of hemophilia.
Materials and methods

Plasmids contruction
The plasmid pCI-Neo was purchased from Promega (Madison, WI, USA) and modified as follows. A mutated dihydrofolate reductase gene (DHFR) under the control of the SV40 promoter as well as the hepatitis virus B 3′ untranslated region (HBV-3′ UTR) were isolated from the RP3224D plasmid 20 digested with PvuII. The isolated fragment was subcloned into the pCI-Neo vector digested by BamHI and blunted by filling in the protruding ends with T4 polymerase resulting in pCI-Neo-DHFR (pCI-ND) plasmid. The mouse phosphoglycerate kinase 1 (PGK-1) promoter was excised from the pCI-PGK-GIP-R /IRES/GLP-1-R vector 46 by BglII/EcoRI digestion and cloned into the BglII/EcoRI isolated pCI-ND backbone giving rise to pPI-ND vector. The mouse metallothionein 1 (MT-1) promoter was removed from the RP3224D plasmid by PCR then digested BglII/PvuII and cloned into the BglII/Ecl136II isolated pCI-Neo backbone resulting in pMI-Neo vector. The mutated DHFR expression cassette from the RP3224D plasmid was subcloned into the pMINeo vector as previously described for the pCI-Neo vector resulting in pMI-ND vector.
The human Epo fragment was isolated from the plasmid pBluescript II SK+ (Stratagene, La Jolla, CA, USA) containing the cDNA for human Epo by EcoRI/NotI digestion and cloned into pCI-ND, pMI-ND and pPI-ND digested by EcoRI/NotI. The BamHI digested mouse Epo cDNA fragment isolated from the pM48 vector was blunted and cloned into pPI-ND digested by SmaI. The integrity of the final constructs pCI-human Epo-ND, pMI-human Epo-ND, pPI-human Epo-ND and pPImouse Epo-ND was confirmed by restriction analysis and sequencing.
Cell culture and transfection of C 2 C 12 cells Mouse C 2 C 12 myoblasts derived from leg skeletal muscle of an adult C3H (H-2 k ) mouse 47 were obtained from American Type Culture Collection (ATCC; CRL 1772, Rockville, MD, USA). C 2 C 12 cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS), 2 mm l-glutamine, 4.5 g/l glucose, 100 U/ml penicillin, 100 U/ml streptomycin. The cells were transfected by calcium phosphate precipitation (mammalian transfection kit; Stratagene) with the following plasmids; pCI-human Epo-ND, pMI-human Epo-ND, pPI-human Epo-ND and pPI-mouse Epo-ND. After 2 weeks of incubation with 0.8 mg/ml G418, cells were incubated with increasing concentrations of methotrexate (1 to 200 m) over a 6-week period to amplify the copy number of the integrated plasmids. Selected pools were obtained by diluting the total population at a final concentration of 10 cells per well.
Epo determination C 2 C 12 cells were plated in growth medium at a density of 1 × 10 5 cells per well in six-well culture dishes (Costar, Cambridge, MA, USA). Differentiated encapsulated cells (see below) were placed in PC-1 medium, a serum-free medium containing human recombinant proteins (Hycor Biomedical, Irvine, CA, USA). Conditioned media were obtained by the incubation of C 2 C 12 cells in 1 ml of fresh medium for 1 h. The samples were stored at −20°C until determination of human Epo concentrations using an enzyme linked immunosorbent assay (ELISA) system (Quantikine IVD; R&D Systems, Minneapolis, MN, USA). Cross-reaction of the kit allowed detection of mouse Epo in culture supernatants. The corrected absolute values of mouse Epo secretion were determined using the Epodependent murine DaE7 cell line as a test of hormone bioactivity. 30 
Cell encapsulation
Control and transfected C 2 C 12 cells were harvested and diluted with culture medium in order to obtain a suspension of 1 × 10 5 cells/l which was then injected into microporous polyethersulfone hollow fibers (OD: 550 m, ID: 350 m) (Azko Nobel Faser, Wupperthal, Germany). One centimeter long capsules were made by cutting them to appropriate lengths and heat sealing the ends. Each capsule contained approximately 2 × 10 5 cells at the time of loading. Capsules were placed for 3 days in DMEM medium containing 10% Prolifix (Bio Media, Boussens, France) at 37°C, 5% CO 2 for cell differentiation. Epo released from each device was subsequently tested by an ELISA assay. The capsules were transfered in PC-1 medium for in vitro studies or implanted in mice.
Subcutaneous capsule implantation in adult mice
Adult female C57BL/6, DBA/2J and C3H mice obtained from Iffa Credo (Saint-Germain sur l'Abresle, France) were anesthetized by inhalation of methoxyflurane (metofane; Mallinckrodt Veterinary, Mundelein, IL, USA). Animals were placed in a prone position for surgery. The capsules were carefully placed on the dorsal flank of the animal through a small skin incision. The skin was closed using resorbable sutures (vicryl 6.0; Ethicon, Norderstedt, Germany). Upon recovery, the mice were returned to the animal care facility where they had access to food and water ad libitum.
Intramuscular injection of mouse EPO secreting C 2 C 12 myoblasts Mouse EPO secreting myoblasts were harvested from confluent cultures by trypsinization, washed three times with Hanks' balanced salt solution (HBSS) and finally resuspended at a concentration of 10 3 -10 5 cells/l HBSS. Adult C3H mice were anesthetized with isofluran and the skin of the hind limb opened for surgery. Using a Hamilton syringe with a 26S-gauge needle, 0.1, 0.3, 1.0, 2.0, 4.0 and 8.0 million cells were respectively injected at five to 10 sites into the tibialis anterior or quadriceps femoris muscles of 10 animals. The skin was then closed using a 6.0 vicryl suture.
Hematocrit measurement
Under methoxyflurane general anesthesia, blood was drawn weekly from the mice tail vein into heparinized capillary tubes. The hematocrit was then measured by a standard microhematocrit method. 48 Capsule histology Capsules kept in vitro and those retrieved from in vivo experiments were fixed in 4% paraformaldehyde with 1% glutaraldehyde for 3 h and dehydrated under an alcohol cycle in preparation for glycol-methacrylate embedding (Leica Instruments, Nussloch, Germany). The capsules were cut at 6 m thickness and stained with cresyl violet and eosin.
Detection of anti-human Epo antibodies in mice sera
A specific immunoperoxidase procedure using the Vectastain ABC system (Vector Laboratories, Burlingame, CA, USA) on nitrocellulose bands was developed. Serial dilutions of human Epo (Eprex; Janssen-Cilag Laboratories, Baar, Switzerland) from 100 ng to 1 ng were blotted on 0.45 m nitrocellulose membranes. Non-specific binding sites were then blocked by incubating the bands with 5% milk in Tris buffer saline (TBS) at pH 7.6. Bands were covered overnight with 60 l of mice sera and phosphate buffer saline (PBS) for negative control, respectively. Biotinylated goat anti-mouse IgG (H+L) (Vector) was incubated with the bands followed by addition of the preformed avidin biotinylated horseradish peroxidase macromolecular complex (ABC) (Vector). Three washes in PBS were performed after each step. Signal detection was achieved using the diaminobenzidine tetrahydrochloride (DAB) chromogen (Pierce, Rockford, IL, USA) which reveals brown spots on the bands.
Statistical analysis
Data are expressed as mean ± s.e.m. The data obtained were analyzed for statistical significance between control and experimental groups using an analysis of variance (ANOVA) followed by a Fischer's PLSD post-hoc test. A P value of less than 0.05 was considered to be statistically significant.
